Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States

Cancer

Volumn 119, Issue 10, 2013, Pages 1916-1923

  Kavcic, Marko ^a   Fisher, Brian T ^a,b   Li, Yimei ^a   Seif, Alix E ^a,b   Torp, Kari ^a   Walker, Dana M ^a,b   Huang, Yuan Shung ^b   Lee, Grace E ^a   Tasian, Sarah K ^a   Vujkovic, Marijana ^a   Bagatell, Rochelle ^a   Aplenc, Richard ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adverse events monitoring; healthcare administrative database; induction mortality; pediatric acute myeloid leukemia; resource utilization

Indexed keywords

ANALGESIC AGENT; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; HYPERTENSIVE FACTOR; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CHILD; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RACE DIFFERENCE; RENAL REPLACEMENT THERAPY; SCHOOL CHILD; THROMBOCYTE TRANSFUSION; UNITED STATES;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FEMALE; HEALTH RESOURCES; HOSPITALS, PEDIATRIC; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; LEUKEMIA, MYELOID, ACUTE; LOGISTIC MODELS; MALE; ODDS RATIO; POISSON DISTRIBUTION; RISK ASSESSMENT; RISK FACTORS; THIOGUANINE; TREATMENT OUTCOME; UNITED STATES;

EID: 84877584544     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27957     Document Type: Article

References (32)

1. Kaspers GJ, Creutzig U,. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005; 19: 2025-2029.
2. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008; 111: 1044-1053.
3. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 2012; 118: 761-769.
4. Gibson BE, Webb DK, Howman AJ, et al. United Kingdom Childhood Leukaemia Working Group and the Dutch Childhood Oncology Group. Results of a randomized trial in children with acute myeloid leukaemia: Medical Research Council AML12 trial. Br J Haematol. 2011; 155: 366-376.
5. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996; 87: 4979-4989.
6. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010; 11: 543-552.
7. Ethier M-C, Blanco E, Lehrnbecher T, Sung L,. Lack of clarity in the definition of treatment-related mortality: pediatric acute leukemia and adult acute promyelocytic leukemia as examples. Blood. 2011; 118: 5080-5083.
8. Sung L, Gamis A, Alonzo TA, et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009; 115: 1100-1108.
9. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005; 293: 203-211.
10. Aplenc R, Alonzo TA, Gerbing RB, et al. Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood. 2006; 108: 74-80.
11. Pui CH, Pei D, Pappo AS, et al. Treatment outcomes in black and white children with cancer: results from the SEER Database and St Jude Children's Research Hospital, 1992 through 2007. J Clin Oncol. 2012; 30: 2005-2012.
12. Kaiser LD, Melemed AS, Preston AJ, et al. Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol. 2010; 28: 5046-5053.
13. Witteles RM, Telli M,. Underestimating cardiac toxicity in cancer trials: lessons learned? J Clin Oncol. 2012; 30: 1916-1918.
14. Juliusson G, Lazarevic V, Hörstedt A-S, Hagberg O, Höglund M, Swedish Acute Leukemia Registry Group. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012; 119: 3890-3899.
15. Fisher BT, Harris T, Torp K, et al. Establishment of an 11-year cohort of 8733 pediatric patients hospitalized at United States free-standing children's hospitals with de novo acute lymphoblastic leukemia from health care administrative data. Med Care. 2012; doi:10.1097/MLR.0b013e31824deff9.
16. Ponsky TA, Huang ZJ, Kittle K, et al. Hospital- and patient-level characteristics and the risk of appendiceal rupture and negative appendectomy in children. JAMA. 2004; 292: 1977-1982.
17. Gerber JS, Newland JG, Coffin SE, et al. Variability in antibiotic use at children's hospitals. Pediatrics. 2010; 126: 1067-1073.
18. Fisher BT, Zaoutis TE, Leckerman KH, Localio R, Aplenc R,. Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study. Pediatr Blood Cancer. 2010; 55: 655-661.
19. Orsey AD, Belasco JB, Ellenberg JH, Schmitz KH, Feudtner C,. Variation in receipt of opioids by pediatric oncology patients who died in children's hospitals. Pediatr Blood Cancer. 2009; 52: 761-766.
20. Aplenc R, Fisher BT, Huang YS, et al. Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group. Pharmacoepidemiol Drug Saf. 2012; 21 (suppl 2): 37-43.
21. Kavcic M, Fisher BT, Torp K, et al. Assembly of a cohort of children treated for acute myeloid leukemia at free-standing children's hospitals in the United States using an administrative database. Pediatric Blood Cancer. 2013; 60: 508-511.
22. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997; 89: 2311-2318.
23. Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia. 2005; 19: 2101-2116.
24. Begg MD, Parides MK,. Separation of individual-level and cluster-level covariate effects in regression analysis of correlated data. Stat Med. 2003; 22: 2591-2602.
25. Localio AR, Berlin JA, Ten Have TR, Kimmel SE,. Adjustments for center in multicenter studies: an overview. Ann Intern Med. 2001; 135: 112-123.
26. Linabery AM, Ross JA,. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer. 2008; 112: 416-432.
27. Scharf O, Colevas AD,. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol. 2006; 24: 3933-3938.
28. Roche K, Paul N, Smuck B, et al. Factors affecting workload of cancer clinical trials: results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2002; 20: 545-556.
29. Bhatia S,. Disparities in cancer outcomes: lessons learned from children with cancer. Pediatric Blood Cancer. 2011; 56: 994-1002.
30. Linabery AM, Ross JA,. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer. 2008; 113: 2575-2596.
31. Rubnitz JE, Lensing S, Razzouk BI, Pounds S, Pui CH, Ribeiro RC,. Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience. Pediatr Blood Cancer. 2007; 48: 10-15.
32. Narus SP, Srivastava R, Gouripeddi R, et al. Federating clinical data from six pediatric hospitals: process and initial results from the PHIS+ Consortium. AMIA Annu Symp Proc. 2011; 2011: 994-1003.